Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2013

View Archived Issues

ImmBio obtains funding to develop multistrain pneumococcal vaccine

Novel potent maturation inhibitors developed by DFH Pharma

Promising antitumor activity seen for NOV-C-ter in vitro and in vivo

MSCT response criteria compared in patients with GIST

Activartis gives update on its anticancer immune therapy for glioma

S100-P as a novel biomarker in patients with gallbladder carcinoma

TFF3 as a biomarker for the prognosis and recurrence of EAC

Astellas files for Japanese approval of ipragliflozin

Kyoto University and Shionogi establish collaboration

MDCT enterography shows promise for diagnosing gastrointestinal tuberculosis

Researchers present data for inclacumab from the SELECT-ACS trial

Scientists at Takeda Pharmaceutical patent new histamine H3 receptor antagonists

Novartis synthesizes new BACE inhibitors

Novel potassium channel blockers presented by Merck & Co.

Boehringer Ingelheim discloses new phosphodiesterase PDE4B inhibitors

Researchers at Roche prepare new protein kinase inhibitors for cancer

Ceregene and ADCS complete enrollment in CERE-110 study

Isis Pharmaceuticals reports phase I data for ISIS-CRPRx

Merck & Co. and Luminex to develop companion diagnostic for MK-8931

N30 Pharmaceuticals treats first patient in phase Ib/IIa trial of N-6022

Scripps Research Institute and Takeda Pharmaceuticals expand research collaboration

French regulatory authorities approve phase I/II trial of BL-8020

FDA clears Quidel's assay for RSV and human MPV

Miraculins enters license agreement regarding biomarker for pregnancy risk

FDA approves Navidea's imaging drug Lymphoseek

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Aug. 15, 2025.
NME Digest: Q2 2025
BioWorld
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
Merck’s MK-2214 shows potential to slow Alzheimer’s pathology
BioWorld Science
Abnormal tau aggregation is a hallmark of Alzheimer’s disease (AD) and a major contributor to neurodegeneration, synaptic dysfunction, and progressive functional...
Scemblix ticks Novartis earnings box; more ahead in CML
BioWorld
Novartis AG’s financial update included good news about Scemblix (asciminib), the first and only U.S. FDA-approved allosteric inhibitor for chronic myeloid...